Business Overview: Aldeyra Therapeutics, Inc. (NASDAQ: ALDX)

---

Executive Summary

Aldeyra Therapeutics, Inc. is a clinical- and early-commercial-stage biopharmaceutical company focused on the discovery and development of medicines to treat immune-mediated and inflammatory diseases, with its lead focus in ophthalmology. Its lead product candidate, reproxalap, is a novel reactive aldehyde species (RASP) modulator being developed (and, following FDA approval, commercialized) for dry eye disease — one of the most common ophthalmic conditions, affecting tens of millions of patients in the United States alone.

Headquartered in Lexington, Massachusetts, Aldeyra's pipeline also includes ADX-2191, an intravitreal formulation of methotrexate being studied for rare retinal and CNS-related indications such as primary vitreoretinal lymphoma, reflecting the company's broader RASP-modulation platform technology applied across multiple inflammatory disease areas.

---

1. Core Business Model & How They Work

Aldeyra's business model follows the typical biopharmaceutical value-creation path: discover and develop novel small-molecule therapeutics, generate clinical proof-of-concept and pivotal trial data, seek FDA approval, and then commercialize approved products — either independently or via partnership — into large but underserved therapeutic markets.

[ RASP-Modulation Platform Discovery ] ➡️ [ Clinical Trials (Reproxalap for Dry Eye, ADX-2191 for Retinal/CNS Indications) ] ➡️ [ FDA Regulatory Review ] ➡️ [ Commercial Launch & Market Access ] ➡️ [ Lifecycle/Label Expansion ]

Key Operational Drivers

1. Novel Mechanism of Action: Reproxalap's RASP-modulating mechanism is differentiated from existing anti-inflammatory dry-eye therapies (such as cyclosporine- or lifitegrast-based products), potentially offering faster onset of action and a different tolerability profile.
2. Large, Underserved Dry Eye Market: Dry eye disease affects a very large patient population, many of whom are dissatisfied with existing treatment options due to slow onset, stinging/burning side effects, or inconsistent efficacy — creating a significant commercial opportunity for a differentiated new therapy.
3. Platform Technology Reuse: The RASP-modulation science underlying reproxalap is also being applied to other inflammatory conditions (e.g., via ADX-2191 for retinal/CNS indications), giving Aldeyra multiple shots on goal from a single core scientific platform.
4. Commercial Build-Out: As reproxalap approaches or achieves approval and launch, Aldeyra must build (or partner for) a specialty ophthalmology sales and marketing capability to compete for prescriber attention in a category dominated by larger pharmaceutical companies.

---

2. Business Segments

Aldeyra operates as a single integrated biopharmaceutical business focused on its RASP-modulation platform, with pipeline activity organized around:

• Reproxalap (Dry Eye Disease): The company's lead, most advanced product candidate targeting the large dry eye disease market.
• ADX-2191 (Retinal/CNS Indications): An intravitreal methotrexate formulation in development for rare and serious retinal/CNS conditions such as primary vitreoretinal lymphoma.
• Earlier-Stage Pipeline: Additional RASP-modulation research applicable to other immune-mediated and inflammatory conditions.

---

3. Product Portfolio & Revenue Contributors

---

4. Competitive Landscape

                    High Ophthalmology/Eye-Care Focus
                                 │
       AbbVie (Allergan, Xiidra) ●│           ● Bausch + Lomb
                                 │
   Novartis ●                    │              ● Aldeyra Therapeutics (reproxalap)
                                 │
─────────────────────────────────┼─────────────────────────────────
   Large-Cap Diversified Pharma   │              Focused Ophthalmology Specialist
                                 │
                          Low Ophthalmology/Eye-Care Focus

Competitors by Domain

Dry Eye Disease Treatment

• Key Competitors: AbbVie (Restasis, Xiidra following the Allergan acquisition), Novartis, Bausch + Lomb, and other specialty ophthalmology companies developing dry eye therapies.
• Dynamics: Existing therapies have well-established prescriber familiarity and payer coverage but are frequently cited by patients and physicians as slow-acting or poorly tolerated; Aldeyra is positioning reproxalap's differentiated mechanism and faster onset of action as a key competitive advantage, but must still overcome the switching inertia of an established prescribing base.

Rare Retinal/CNS Disease

• Key Competitors: Various specialty and orphan-disease-focused biopharmaceutical companies developing therapies for rare retinal lymphoma and related conditions.
• Dynamics: This is a smaller, more specialized competitive arena where clinical differentiation and orphan-drug incentives (if applicable) play a larger role than broad commercial scale.

---

5. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• Differentiated mechanism of action: Reproxalap's RASP-modulation approach is mechanistically distinct from existing dry-eye therapies, providing a genuine basis for clinical and marketing differentiation if approval is achieved.
• Patent protection on core platform chemistry: Aldeyra holds intellectual property around its RASP-modulator compounds, providing a period of exclusivity if products reach the market.
• Multiple applications of a single scientific platform: The RASP-modulation science underlying reproxalap extends to other pipeline candidates, providing platform-level optionality beyond a single product bet.

Strategic Risks & Vulnerabilities

1. Regulatory approval risk: As with any clinical-stage biopharmaceutical program, reproxalap and other pipeline candidates face inherent risk of trial failure or regulatory rejection/delay.
   • Mitigation Strategy: Pursuing a robust, well-designed clinical trial program to build a strong efficacy and safety data package for regulatory review.
2. Commercial launch execution risk: Successfully launching into the competitive dry eye market requires building specialty sales/marketing capability and securing payer formulary access against entrenched, larger competitors.
   • Mitigation Strategy: Potential partnership arrangements to leverage an established ophthalmology commercial infrastructure if needed.
3. Reliance on a concentrated pipeline: With reproxalap representing the large majority of near-term value, any setback to this program would have an outsized impact on the company.
   • Mitigation Strategy: Continued investment in the broader RASP-modulation pipeline (e.g., ADX-2191) to diversify long-term value drivers.

---

6. Financial Overview & Performance Matrix

---

7. Summary Conclusion

Aldeyra Therapeutics has built a differentiated RASP-modulation platform anchored by reproxalap, a novel-mechanism candidate targeting the large and underserved dry eye disease market, alongside a smaller rare-disease program in ADX-2191. The scientific differentiation of its core platform provides a credible basis for competing against entrenched dry-eye therapies from much larger pharmaceutical companies.

The company's long-term trajectory depends heavily on successful regulatory approval and commercial execution for reproxalap — converting its mechanistic and clinical differentiation into real prescriber adoption and payer coverage against well-established competitors — while continuing to advance its broader RASP-modulation pipeline as a hedge against any single-program setback.